Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052313 | 0.86 | CDK1 (0.62) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL1672138 | 0.86 | CDK1 (0.62) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL9388321 | 0.84 | CYP2C19 (0.47) | HDAC6HDAC1HDAC4CYP2C19 | |
| SCHEMBL7872842 | 0.83 | HSP90AB1 (0.55) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL8649570 | 0.81 | HSP90AB1 (0.55) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL8768015 | 0.80 | HSP90AB1 (0.52) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL31058755 | 0.80 | HDAC6 (0.54) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL8839795 | 0.80 | HDAC6 (0.52) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL19245704 | 0.80 | HSP90AB1 (0.56) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL27854926 | 0.80 | CDK1 (0.71) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551210-A1 | BIFACIAL PEPTIDE NUCLEIC ACID PROBES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010977-A1 | BIFACIAL PEPTIDE NUCLEIC ACID PROBES AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-107447215-B | Etching solution composition for copper-based metal film and method of manufacturing array substrate for liquid crystal display device using the same | 东友精细化工有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-106148961-A | Etching agent composite, formation metal line pattern method and manufacturing array substrate approach | 东友精细化工有限公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20120115136-A1 | PNA DIAGNOSTIC USE | PNA Patent Owners (a/k/a CIG) (US) | 2012-05-10 | — | — | US | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1074559-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2011-07-06 | — | — | EP | disclosed |
| CN-101910168-A | Tropane compounds | EXELIXIS INC | 2010-12-08 | — | — | CN | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-5539082-A | Peptide nucleic acids | NIELSEN PETER E (DK) | 1996-07-23 | — | — | US | disclosed |
| WO-1996020212-A2 | PEPTIDE NUCLEIC ACID INCORPORATING A CHIRAL BACKBONE | BUCHARDT, DORTE (DK) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996002558-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1994012213-A1 | METHOD OF PRODUCING ANTIBODIES WITH CONJUGATES OF B-CELL-ANTIGEN AND DENATURED CARRIER | BUCHARDT OLE (DK) | 1994-06-09 | — | — | WO | disclosed |
| EP-0586618-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES. | BUCHARDT OLE (DK) | 1994-03-16 | — | — | EP | disclosed |
| EP-0586474-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT, Ole (DK) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020703-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020702-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | RNASE1, NCL, PABPC4 | HDAC6 1949/4885HDAC1 4277/4885HDAC4 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.